pioglitazone has been researched along with Hyperaldosteronism in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Hyperaldosteronism: A condition caused by the overproduction of ALDOSTERONE. It is characterized by sodium retention and potassium excretion with resultant HYPERTENSION and HYPOKALEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR γ agonist pioglitazone." | 7.79 | Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. ( Harada, E; Kashiwagi, Y; Mizuno, Y; Morita, S; Shono, M; Yano, M; Yasue, H; Yoshimura, M, 2013) |
| " We report a case of 55-year-old man with primary aldosteronism (PA) whose hyperaldosteronism was suppressed with the PPAR γ agonist pioglitazone." | 3.79 | Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone. ( Harada, E; Kashiwagi, Y; Mizuno, Y; Morita, S; Shono, M; Yano, M; Yasue, H; Yoshimura, M, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kashiwagi, Y | 1 |
| Mizuno, Y | 1 |
| Harada, E | 1 |
| Shono, M | 1 |
| Morita, S | 1 |
| Yoshimura, M | 1 |
| Yano, M | 1 |
| Yasue, H | 1 |
1 other study available for pioglitazone and Hyperaldosteronism
| Article | Year |
|---|---|
Suppression of primary aldosteronism and resistant hypertension by the peroxisome proliferator-activated receptor gamma agonist pioglitazone.
Topics: Aldosterone; Blood Pressure; Comorbidity; Humans; Hyperaldosteronism; Hypertension; Male; Middle Age | 2013 |